Streetbeat News

Analyst Ratings

OCUP

HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Ocuphire Pharma (NASDAQ:OCUP) and maintained a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:36 am

ADP

Mizuho analyst Dan Dolev has maintained a Buy rating on Automatic Data Processing (ADP) and increased the price target from $265 to $272.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:36 am

AQST

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Aquestive Therapeutics (NASDAQ:AQST) and increased the price target from $6 to $7.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:34 am

CCOI

MoffettNathanson analyst Nick DelDeo maintains a Buy rating on Cogent Communications Holdings (CCOI) and raises the price target from $95 to $105.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:33 am

STZ

Barclays analyst Adrienne Yih maintains an Overweight rating on Constellation Brands (NYSE:STZ) and raises the price target from $179 to $194.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:30 am

STZ

Wells Fargo analyst Chris Carey has maintained an Overweight rating on Constellation Brands (NYSE:STZ) and increased the price target from $285 to $295.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:28 am

BWAY

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on BrainsWay (NASDAQ:BWAY) and increased the price target from $12 to $13.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:27 am

TSM

Bernstein analyst Mark Li maintains an Outperform rating on Taiwan Semiconductor (NYSE:TSM) and raises the price target from $125 to $150.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:26 am

KRTX

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Neutral rating on Karuna Therapeutics (NASDAQ:KRTX) and maintained a $330 price target.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:25 am

SATS

JP Morgan analyst Philip Cusick has maintained a Neutral rating on EchoStar (NASDAQ:SATS) but has lowered the price target from $18 to $12.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:25 am